DUBLIN, Dec. 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Jonathon Kellerman has joined the Company as Executive Vice President, Global Chief Compliance Officer. Mr. Kellerman is a member of the Actavis Executive Leadership Team (ELT) and will report directly to Brent Saunders, CEO and President. He will also be an integral member of the Actavis and Allergan pre-integration planning team as well as integration activities following the close.
"Jonathon brings nearly 20 years of experience in helping companies integrate compliance into the value chain and establish a vision for the future of how to effectively manage global risk by focusing on innovative solutions in compliance strategy, operations and process," said Saunders. "We look forward to his contribution in strengthening Actavis' commitment to effective global compliance programs."
Mr. Kellerman joins Actavis from PwC, where he was a partner in PwC's Pharmaceutical and Life Sciences Advisory practice, responsible for helping lead the firm's Governance, Risk & Compliance practice, including a global team of over 100 diverse professionals. Mr. Kellerman brings extensive experience in compliance and sales and marketing performance improvement, including global anti-bribery/anti-corruption program assessment, design and implementation work; building and implementing effective global compliance programs; managing fraud investigations and remediation activities; re-engineering processes supporting key commercial and R&D business activities and compliance controls; and re-designing how companies engage health care professionals. He has also led major "rapid response" organizational and business process improvement initiatives across multiple business and support functions. Earlier in his career, Mr. Kellerman worked in Healthcare Consulting for Zelenkofske Axelrod and in Research for Blank Rome.
Mr. Kellerman is a recognized industry thought leader on the future of compliance strategy, organization and function vis-à-vis a rapidly changing business model and regulatory landscape and has been a frequent contributor to white papers, industry publications and conferences. He has a BA in Sociology from Franklin & Marshall College.
Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.
Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.
For more information, visit Actavis' website at www.actavis.com.
Investors: Lisa DeFrancesco (862) 261-7152
Media: Charlie Mayr (862) 261-8030
David Belian (862) 261-8141
SOURCE Actavis plc